AOD-9604 vs MOTS-c

Peptide researchers exploring metabolic pathways often encounter both AOD-9604 and MOTS-c. These two peptides, while both studied for specific therapeutic applications, operate through fundamentally different mechanisms.

AOD-9604 is a modified growth hormone fragment peptide, researched primarily for fat loss, metabolic health. Its half-life is estimated 2–3 hours (limited pharmacokinetic data). Administration is typically via subcutaneous, oral.

MOTS-c is a mitochondrial-derived peptide (MDP), studied for metabolic health, anti-aging/longevity, fat loss. Its half-life is short in plasma (minutes); cellular effects persist. Administration is typically via subcutaneous, intraperitoneal, intravenous.

Here we compare these two compounds side-by-side so you can determine which might better serve your research protocol — or whether they could work together. [PMID: 27060479]; [PMID: 25565208]; [PMID: 11739441]

AOD-9604 operates primarily through Stimulation of lipolysis via beta-3-adrenergic receptor pathway; Inhibition of lipogenesis without affecting blood glucose or IGF-1. Its preclinical research supports applications in fat loss, metabolic health.

MOTS-c works through Activation of AMPK signaling pathway improving insulin sensitivity; Inhibition of folate cycle and de novo purine biosynthesis; Nuclear translocation and transcriptional regulation of metabolic genes. Its preclinical research supports applications in metabolic health, anti-aging/longevity, fat loss.

Both AOD-9604 and MOTS-c are synthetic peptides studied in preclinical, preclinical research. They share research interest in fat loss, metabolic health. Both are administered subcutaneously. Both have published research supporting their mechanisms of action.

The key difference lies in mechanism and half-life. AOD-9604 (estimated 2–3 hours (limited pharmacokinetic data)) and MOTS-c (short in plasma (minutes); cellular effects persist) have distinct pharmacokinetic profiles. AOD-9604 targets fat loss, metabolic health primarily, while MOTS-c focuses more on metabolic health, anti-aging/longevity. Their molecular origins differ significantly: AOD-9604 derives from modified growth hormone fragment peptide, whereas MOTS-c originates from mitochondrial-derived peptide (MDP).

Choose AOD-9604 if your research focuses on fat loss, metabolic health. Its estimated 2–3 hours (limited pharmacokinetic data) half-life shapes its dosing protocol. Its primary mechanisms — Stimulation of lipolysis via beta-3-adrenergic receptor pathway; Inhibition of lipogenesis without affecting blood glucose or IGF-1 — make it the better fit for fat loss-focused protocols.

Choose MOTS-c if you're studying metabolic health, anti-aging/longevity. Its short in plasma (minutes); cellular effects persist half-life means dosing. Its mechanisms — Activation of AMPK signaling pathway improving insulin sensitivity; Inhibition of folate cycle and de novo purine biosynthesis — are better suited for metabolic health-oriented research.